Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">p53 signalling altered in 87%</td><td class="align_center">MDM2 (amplification in 14%)</td></tr><tr><td class="align_left">RTK/RAS/PI3 signalling altered in 88%</td><td class="align_center">PI3K (mutation in 15%)</td></tr><tr><td class="align_left">RB signaling altered in 78%</td><td class="align_center">CDK4 (amplification in 18%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

BioMed Research International

tab1

Table 1

Table 1: Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives 